obesity

News

Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.

News

Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.

News

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for Sciwind-sourced ecnoglutide.

News

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

News

Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.